PDF

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This guideline develops a framework to evaluate existing clinical practice guidelines for prescribing opioids for acute pain indications and recommends indications for which new evidence-based guidelines should be developed.

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.

This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.

Based on 2020 and earlier NSDUH data, this report contains findings on a wide variety of key substance use and mental health indicators in the United States.

These estimated costs of opioid use disorder and fatal opioid overdose and their per capita costs at the state level can assist federal and state decision makers in understanding the magnitude of opioid use disorder and fatal opioid overdose in their jurisdictions.

This toolkit gives practice principles for integrated treatment for mental illness, substance use disorders, or both, and offers advice from successful programs. It includes a brochure, a PowerPoint presentation, and a introductory video.

This Spanish language data visualization illustrates the correlation between alcohol use and other substance use to inform parents/guardians and communities.